About: Identification of synthetic vaccine candidates against SARS CoV infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Identification of synthetic vaccine candidates against SARS CoV infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Identification of synthetic vaccine candidates against SARS CoV infection
Creator	Lien, Shu-Pei Shih, Yi-Ping Leng, Chih-Hsiang Chang, Yu-Wen Chen, Hsin-Wei Chong, Pele Chou, Ai-Hsiang Lin, Li-Hsiu Lin, Min-Han Liu, Hsin-Yu Liu, Shih-Jen Tsai, Jy-Ping Chen, Yi-Ming
Source	Elsevier; Medline; PMC
abstract	Abstract Three peptides, D1 (amino acid residues 175–201), D2 (a.a. 434–467), and TM (a.a. 1128–1159), corresponding to the spike protein (S) of severe acute respiratory syndrome corona virus (SARS CoV) were synthesized and their immunological functions were investigated in three different animals models (mice, guinea pigs, and rabbits). The peptides mixture formulated either with Freund’s adjuvant or synthetic adjuvant Montanide ISA-51/oligodeoxy nucleotide CpG (ISA/CpG) could elicit antisera in immunized animals which were capable of inhibiting SARS/HIV pseudovirus entry into HepG2 cells. The neutralizing epitopes were identified using peptides to block the neutralizing effect of guinea pig antisera. The major neutralizing epitope was located on the D2 peptide, and the amino acid residue was fine mapped to 434–453. In BALB/c mice T-cell proliferation assay revealed that only D2 peptide contained T-cell epitope, the sequence of which corresponded to amino acid residue 434–448. The ISA/CpG formulation generated anti-D2 IgG titer comparable to those obtained from Freund’s adjuvant formulation, but generated fewer antibodies against D1 or TM peptides. The highly immunogenic D2 peptide contains both neutralizing and Th cell epitopes. These results suggest that synthetic peptide D2 would be useful as a component of SARS vaccine candidates.
has issue date	2007-07-06(xsd:dateTime)
bibo:doi	10.1016/j.bbrc.2007.04.164
bibo:pmid	17506989
has license	els-covid
sha1sum (hex)	8db46c95335092ee2f42eb7e8f943d7edef7b407
schema:url	https://doi.org/10.1016/j.bbrc.2007.04.164
resource representing a document's title	Identification of synthetic vaccine candidates against SARS CoV infection
has PubMed Central identifier	PMC7092873
has PubMed identifier	17506989
schema:publication	Biochemical and Biophysical Research Communications
resource representing a document's body	covid:8db46c95335092ee2f42eb7e8f943d7edef7b407#body_text
is schema:about of	named entity 'rabbits' named entity 'generated' named entity 'adjuvant' named entity 'T-cell' named entity 'amino acid' named entity 'acid' named entity 'severe acute respiratory syndrome' named entity 'neutralizing' named entity 'mice' named entity 'peptide' named entity 'Freund' covid:arg/8db46c95335092ee2f42eb7e8f943d7edef7b407 named entity 'identified' named entity 'cell' named entity 'spike' named entity 'CpG' named entity 'proliferation' named entity 'HIV' named entity 'a.a.' named entity 'adjuvant' named entity 'The major' named entity 'pseudovirus' named entity 'peptide' named entity 'peptide' named entity 'neutralizing' named entity 'protein' named entity 'titer' named entity 'animals' named entity 'Three' named entity 'comparable' named entity 'pig' named entity 'peptide' named entity 'pseudovirus' named entity 'immunogenic' named entity 'epitopes' named entity 'amino acid residue' named entity 'peptides' named entity 'T-cell' named entity 'peptide' named entity 'epitope' named entity 'epitopes' named entity 'peptide' named entity 'antibodies' named entity 'peptides' named entity 'adjuvant' named entity 'infection' named entity 'antigenicity' named entity 'lysed' named entity 'PBS' named entity 'immunizations' named entity 'antigenicity' named entity 'amino acid' named entity 'vaccine design' named entity 'antisera' named entity 'monoclonal antibody' named entity 'spike protein' named entity 'Germany' named entity 'T-cell' named entity 'T-cells' named entity 'virus entry' named entity 'spike protein' named entity 'nucleotide' named entity 'virus' named entity 'epitope' named entity 'amino acid residue' named entity 'vaccine' named entity 'immunization' named entity '1.6' named entity 'peptide'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software